In last trading session, Alaunos Therapeutics Inc. (NASDAQ:TCRT) saw 8.77 million shares changing hands with its beta currently measuring 0.15. Company’s recent per share price level of $2.01 trading at -$0.53 or -20.87% at ring of the bell on the day assigns it a market valuation of $366.70M. That closing price of TCRT’s stock is at a discount of -99.5% from its 52-week high price of $4.01 and is indicating a premium of 79.6% from its 52-week low price of $0.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 9.95 million shares which gives us an average trading volume of 3.94 million if we extend that period to 3-months.
For Alaunos Therapeutics Inc. (TCRT), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.30. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.07 in the current quarter.
Alaunos Therapeutics Inc. (NASDAQ:TCRT) trade information
Upright in the red during last session for losing -20.87%, in the last five days TCRT remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $2.01 price level, adding 46.11% to its value on the day. Alaunos Therapeutics Inc.’s shares saw a change of 84.40% in year-to-date performance and have moved -40.71% in past 5-day. Alaunos Therapeutics Inc. (NASDAQ:TCRT) showed a performance of 23.31% in past 30-days. Number of shares sold short was 28.87 million shares which calculate 8.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $4.20 to the stock, which implies a rise of 52.14% to its current value. Analysts have been projecting $2.00 as a low price target for the stock while placing it at a high target of $7.50. It follows that stock’s current price would drop -273.13% in reaching the projected high whereas dropping to the targeted low would mean a gain of 0.5% for stock’s current value.
Alaunos Therapeutics Inc. (TCRT) estimates and forecasts
Statistics highlight that Alaunos Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 182.34% of value to its shares in past 6 months, showing an annual growth rate of 45.95% while that of industry is 11.70. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 36.40% in the current quarter and calculating 36.40% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 22.60% during past 5 years.
Alaunos Therapeutics Inc. is more likely to be releasing its next quarterly report in October and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Alaunos Therapeutics Inc. (NASDAQ:TCRT)’s Major holders
Insiders are in possession of 10.60% of company’s total shares while institution are holding 53.73 percent of that, with stock having share float percentage of 60.10%. Investors also watch the number of corporate investors in a company very closely, which is 53.73% institutions for Alaunos Therapeutics Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at TCRT for having 16.7 million shares of worth $10.9 million. And as of Mar 30, 2022, it was holding 7.74% of the company’s outstanding shares.
The second largest institutional holder is MSD Partners, L.P., which was holding about 15.15 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 7.02% of outstanding shares, having a total worth of $9.88 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 30, 2022, the former fund manager was holding 4.98 million shares of worth $3.25 million or 2.30% of the total outstanding shares. The later fund manager was in possession of 3.1 million shares on Mar 30, 2022, making its stake of worth around $2.02 million in the company or a holder of 1.43% of company’s stock.